- Castle Biosciences, Inc. ( NASDAQ: CSTL ), a cancer-focused diagnostics company, added ~8% on Tuesday after announcing new data supporting its TissueCypher test, which is designed to predict high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s esophagus (BE).
- According to the company, data from a 154-patient group indicated that 58.4% of subjects had a 100% probability of receiving suitable cancer management with the use of the TissueCypher test compared to 9.1% who were subject to the standard of care pathology review only.
- Castle ( CSTL ) said that the results demonstrate the importance of using the Laboratory Developed Test to improve the management of BE patients with low-grade dysplasia (LGD).
- The analysis was part of a presentation at the ongoing 2022 American College of Gastroenterology (ACG2022) Annual Scientific Meeting.
- “We believe there are potential implications to this finding, including a reduction in the incidence and mortality of esophageal cancer and a reduction in the use of unnecessary clinical treatments, when appropriate,” said Lucas Duits, M.D., Ph.D. who presented the data.
- Dr. Duits is a gastroenterologist at the Department of Gastroenterology and Hepatology at the University Medical Center in Amsterdam.
For further details see:
Castle Biosciences rises on new data for TissueCypher esophageal cancer test